Compounds for targeted therapies of castration resistant prostate cancer
OwnerGaurav Choprainventor
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to new compounds for therapeutic uses. In particular, this disclosure relates to novel tetracyclic compounds useful for treatment of cancer, especially castration resistant prostate cancer. Pharmaceutical composition matters and methods for treating a cancer patient by administering therapeutically effective amounts of such compound alone or together with other therapeutics are within the scope of this disclosure.
Claims25
A compound having the formula:
- or a pharmaceutically acceptable salt thereof, wherein
- represents a single or double bond, wherein when represents a single bond, X is a hydroxyl or alkyloxy;
- or when represents a double bond, X is O, S, NH, N—OH, N—NH2, or NR7, wherein R7 is an C1-C6 alkyl;
- R1 and R2 are independently hydrogen, a C1 to C6 alkyl, alkenyl or alkynyl;
- R3 is hydrogen, hydroxyl, thiol, halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;
- and
- R4 is absent or hydrogen, hydroxyl, halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating a cancer patient, comprising the step of administering a therapeutically effective amount of one or more compounds, together with one or more carriers, diluents, or excipients, to a patient in need of relief from said cancer, at least one of the compounds having the formula:
- or a pharmaceutically acceptable salt thereof, wherein
- represents a single or double bond, wherein when represents a single bond, X is a hydroxyl or alkyloxy;
- or when represents a double bond, X is O, S, NH, N—OH, N—NH2, or NR7, wherein R7 is an C1-C6 alkyl;
- R1 and R2 are independently hydrogen, a C1 to C6 alkyl, alkenyl or alkynyl;
- R3 is hydrogen, hydroxyl, thiol, halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, thiolalkyl, mercaptoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;
- and
- R4 is hydrogen, hydroxyl, halo, azido, nitro, cyano, an alkyl, alkenyl, alkynyl, alkylalkynyl, alkyloxy, hydroxyalkyl, aminoalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted.
Dependencies are inferred from the claim text.